Another, long-established company has been the poster child for stem cell therapy however, there’s several smaller and promising regenerative medicine companies that are doing things differently and making rapid progress. And this includes Cynata addressing the complexities and challenges of manufacturing MSCs at a commercial scale, producing essentially infinite quantities of consistent and potent MSCs from a single donor from a single blood donation.